GLP 1 Drugs Offer Hope to Women Suffering from PMOS, But Access is a Growing Concern Research on GLP 1 drugs as a potential treatment for polyendocrine metabolic ovarian syndrome (PMOS) has sparked hope for women like Charlotte Touzalin and her mother Anne Schultz.
They have struggled with debilitating symptoms of PMOS, including insulin resistance, abnormal periods, and unwanted facial hair.
After participating in a study testing GLP 1 drugs, Touzalin's symptoms began to improve significantly.